Get all premium features to the best stock analysis tool

New initiative from Silo Pharma designed to align with federal actions to accelerate mental health innovation using psychedelic medicines

Federal initiatives focused on PTSD and related conditions appears to validate need for new and novel approaches to mental health treatment

Launch of Dedicated AI Subsidiary Positions Company for New Revenue Streams While Advancing PTSD Program Toward Phase 1 SARASOTA, FL, April 22, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced a strategic business expansion into AI technology as a second line of business resulting from its recent purchase of the assets of Qwikagents.ai, an AI platform designed to support the deployment of autonomous AI agents.  “We expect that Silo's diversification into AI infrastructure will enable it to take advantage of opportunities in high-growth, transformative technologies that we believe are driving the current tech economy,” said Eric Weisblum, Chief Executive Officer.

Silo said the European Patent Office issued a Rule 71(3) communication indicating its intent to grant a patent for the application, which the company has an exclusive license from Columbia University.

Meanwhile, Iran has submitted a 10-point response to the U.S. peace proposals, which a U.S. official described as "maximalist", citing the Iranian state news agency IRNA.

EPO Greenlights Claims Covering Preventative use of therapy targeting 5-HT4 Pathway and Expands Silo Pharma IP Portfolio SARASOTA, FL, April 06, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that the European Patent Office (EPO) has issued a Rule 71(3) communication indicating its intent to grant a patent for an European patent application titled “Prophylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress” (European Patent Application No. 20786878.7) that the Company has an exclusive license from Columbia University.

Sarasota, FL, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that its board of directors has authorized a share repurchase program to acquire up to $1million of the Company's common stock. The Company may purchase common stock on the open market, through privately negotiated transactions, or otherwise, in compliance with the rules of the United States Securities and Exchange Commission and other applicable legal requirements.   The Company had 13,318,273 shares of common stock outstanding as of November 13, 2025, as reported in its Quarterly Report for the period ended September 30, 2025.